J&J's Caplyta meets main goal in bipolar mania phase 3 trial
J&J’s Caplyta cut manic symptoms 4.8 YMRS points more than placebo at Week 3 in Phase 3 Study 451; not yet approved for bipolar mania.
Health · 7 sources · Sep 22, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About bipolar disorder
Bipolar disorder (BD), previously known as manic depression, is a mental disorder characterized by periods of depression and abnormally elevated mood, lasting days to weeks, and in some cases months. If the elevated mood is severe or associated with psychosis, it is called mania; if it does not significantly affect functioning, it is called hypomania. During mania, an individual behaves or feels abnormally energetic, happy, or irritable, and often makes impulsive and reckless decisions. There is usually sleep disturbance during manic phases. During periods of depression, the individual may experience crying, have a negative outlook, and demonstrate poor eye contact. People with BD are at 11.7 times greater risk of dying by suicide than the general population. Approximately 34% attempt suicide during their lifetime. Among adolescents with BD, 78% engaged in self-harm.
Everything about bipolar disorder →